BCEL Atreca Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCEL

Price (delayed)

$1.28

Market cap

$50.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.76

Enterprise value

$93.79M

Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique ...

Highlights
Atreca's EPS has increased by 4.8% QoQ
BCEL's net income is up by 3.9% QoQ but it is down by 2.4% YoY
Atreca's equity has decreased by 45% YoY and by 16% from the previous quarter
Atreca's quick ratio has decreased by 38% YoY and by 22% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.atreca.com
Peers: OVID

Key stats

What are the main financial stats of BCEL
Market
Shares outstanding
39.07M
Market cap
$50.01M
Enterprise value
$93.79M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$105.33M
EBITDA
-$98.69M
Free cash flow
-$85.77M
Per share
EPS
-$2.76
Free cash flow per share
-$2.22
Book value per share
$2.49
Revenue per share
$0
TBVPS
$4.44
Balance sheet
Total assets
$172.08M
Total liabilities
$75.82M
Debt
$64.69M
Equity
$96.25M
Working capital
$78.21M
Liquidity
Debt to equity
0.67
Current ratio
6.37
Quick ratio
5.88
Net debt/EBITDA
-0.44
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-54.2%
Return on equity
-83.6%
Return on invested capital
-58.1%
Return on capital employed
-66.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCEL stock price

How has the Atreca stock price performed over time
Intraday
1.59%
1 week
-8.57%
1 month
-16.88%
1 year
-62.35%
YTD
59.88%
QTD
59.88%

Financial performance

How have Atreca's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$106.5M
Net income
-$105.33M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 3.8% from the previous quarter but it has contracted by 2.1% YoY
BCEL's net income is up by 3.9% QoQ but it is down by 2.4% YoY

Growth

What is Atreca's growth rate over time

Valuation

What is Atreca stock price valuation
P/E
N/A
P/B
0.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Atreca's EPS has increased by 4.8% QoQ
Atreca's equity has decreased by 45% YoY and by 16% from the previous quarter
The stock's price to book (P/B) is 27% less than its last 4 quarters average of 0.7

Efficiency

How efficient is Atreca business performance
BCEL's ROE has shrunk by 70% YoY and by 11% QoQ
BCEL's return on assets is down by 31% year-on-year
The company's return on invested capital rose by 19% YoY and by 19% QoQ

Dividends

What is BCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCEL.

Financial health

How did Atreca financials performed over time
BCEL's total assets is 127% more than its total liabilities
The total liabilities has surged by 69% year-on-year
Atreca's quick ratio has decreased by 38% YoY and by 22% from the previous quarter
BCEL's debt is 33% lower than its equity
Atreca's equity has decreased by 45% YoY and by 16% from the previous quarter
BCEL's debt to equity is up by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.